ID23014A - INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER - Google Patents

INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER

Info

Publication number
ID23014A
ID23014A IDW991597A ID991597A ID23014A ID 23014 A ID23014 A ID 23014A ID W991597 A IDW991597 A ID W991597A ID 991597 A ID991597 A ID 991597A ID 23014 A ID23014 A ID 23014A
Authority
ID
Indonesia
Prior art keywords
inhibitors
transferage
reducture
farnesil
combination
Prior art date
Application number
IDW991597A
Other languages
English (en)
Indonesian (id)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfrizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfrizer Products Inc filed Critical Pfrizer Products Inc
Publication of ID23014A publication Critical patent/ID23014A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW991597A 1997-06-16 1998-06-05 INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER ID23014A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
ID23014A true ID23014A (id) 1999-12-30

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991597A ID23014A (id) 1997-06-16 1998-06-05 INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER

Country Status (37)

Country Link
EP (1) EP0986387B1 (hu)
JP (1) JP3713051B2 (hu)
KR (1) KR100392573B1 (hu)
CN (1) CN1259868A (hu)
AP (1) AP9801261A0 (hu)
AR (1) AR013090A1 (hu)
AT (1) ATE235905T1 (hu)
BG (1) BG103946A (hu)
BR (1) BR9810616A (hu)
CA (1) CA2294399C (hu)
CO (1) CO4950607A1 (hu)
DE (1) DE69812933T2 (hu)
DK (1) DK0986387T3 (hu)
DZ (1) DZ2518A1 (hu)
EA (1) EA199901043A1 (hu)
ES (1) ES2196559T3 (hu)
GT (1) GT199800081A (hu)
HN (1) HN1998000091A (hu)
HR (1) HRP980328B1 (hu)
HU (1) HUP0004624A3 (hu)
ID (1) ID23014A (hu)
IL (1) IL132765A0 (hu)
IS (1) IS5259A (hu)
MA (1) MA24569A1 (hu)
NO (1) NO996206L (hu)
NZ (1) NZ500662A (hu)
OA (1) OA11231A (hu)
PA (1) PA8453601A1 (hu)
PE (1) PE82899A1 (hu)
PL (1) PL337651A1 (hu)
PT (1) PT986387E (hu)
SK (1) SK169699A3 (hu)
TN (1) TNSN98088A1 (hu)
TR (1) TR199903074T2 (hu)
UA (1) UA57081C2 (hu)
WO (1) WO1998057633A1 (hu)
ZA (1) ZA985182B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077949A2 (en) 1998-05-12 2001-02-28 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド,インク. 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
AU7445998A (en) 1999-01-04
AU724676B2 (en) 2000-09-28
CO4950607A1 (es) 2000-09-01
JP3713051B2 (ja) 2005-11-02
PL337651A1 (en) 2000-08-28
KR20010013839A (ko) 2001-02-26
DE69812933D1 (de) 2003-05-08
ZA985182B (en) 1999-12-17
EP0986387A1 (en) 2000-03-22
HUP0004624A2 (hu) 2001-10-28
PA8453601A1 (es) 2000-05-24
HRP980328A2 (en) 1999-04-30
HRP980328B1 (en) 2002-06-30
EA199901043A1 (ru) 2000-06-26
CN1259868A (zh) 2000-07-12
DZ2518A1 (fr) 2003-02-01
MA24569A1 (fr) 1998-12-31
BR9810616A (pt) 2000-09-12
PT986387E (pt) 2003-06-30
DK0986387T3 (da) 2003-07-14
IL132765A0 (en) 2001-03-19
AP9801261A0 (en) 1999-12-11
NO996206D0 (no) 1999-12-15
HUP0004624A3 (en) 2002-11-28
UA57081C2 (uk) 2003-06-16
TNSN98088A1 (fr) 2005-03-15
NO996206L (no) 2000-02-15
ATE235905T1 (de) 2003-04-15
SK169699A3 (en) 2000-06-12
DE69812933T2 (de) 2003-11-06
WO1998057633A1 (en) 1998-12-23
IS5259A (is) 1999-11-19
PE82899A1 (es) 1999-08-26
CA2294399A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
NZ500662A (en) 2001-10-26
AR013090A1 (es) 2000-12-13
BG103946A (bg) 2000-07-31
EP0986387B1 (en) 2003-04-02
GT199800081A (es) 1999-12-07
TR199903074T2 (xx) 2000-05-22
ES2196559T3 (es) 2003-12-16
KR100392573B1 (ko) 2003-07-23
OA11231A (en) 2003-05-26

Similar Documents

Publication Publication Date Title
FI963597A (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
NO962269D0 (no) Enzyminhibitorer
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
NO942064D0 (no) yminhibitorer
ID19198A (id) Inhibitor metaloprotease heterosiklik
DK2028186T3 (da) Hepatitis C inhibitor tri-peptider
ID18416A (id) Inhibitor metaloprotease diheterosiklik
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
ID24076A (id) Inhibitor-inhibitor protein transferase farnesil
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
NO990296D0 (no) HPPD-genet og inhibitorer
NO996578D0 (no) Urokinase-inhibitorer
NO20004550D0 (no) Enzyminhibitorer
PT1047450E (pt) Combinacoes inibidor ace - inibidor mmp
ID23014A (id) INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER
DE59806475D1 (de) Urokinase-inhibitoren
FI971156A (fi) 5alfa-reduktaasi-inhibiittoreita
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20005680L (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
NO20001835D0 (no) WOF inhibitor
MA24877A1 (fr) INHIBITEURS DE PROTéASES
DE69720957T2 (de) Ace-hemmer
BR9610514A (pt) Inibidores cicloantihelmínticos
SI0986387T1 (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER